SE8400788D0 - Novel adenosine receptor antagonists - Google Patents

Novel adenosine receptor antagonists

Info

Publication number
SE8400788D0
SE8400788D0 SE8400788A SE8400788A SE8400788D0 SE 8400788 D0 SE8400788 D0 SE 8400788D0 SE 8400788 A SE8400788 A SE 8400788A SE 8400788 A SE8400788 A SE 8400788A SE 8400788 D0 SE8400788 D0 SE 8400788D0
Authority
SE
Sweden
Prior art keywords
receptor antagonists
adenosine receptor
novel adenosine
novel
phenylxanthines
Prior art date
Application number
SE8400788A
Other languages
English (en)
Other versions
SE8400788L (sv
SE456680B (sv
Inventor
S H Snyder
J W Daly
R F Bruns
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SE8400788D0 publication Critical patent/SE8400788D0/sv
Publication of SE8400788L publication Critical patent/SE8400788L/sv
Publication of SE456680B publication Critical patent/SE456680B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
SE8400788A 1983-02-18 1984-02-14 Derivat av 8-fenylxantin SE456680B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,894 US4593095A (en) 1983-02-18 1983-02-18 Xanthine derivatives

Publications (3)

Publication Number Publication Date
SE8400788D0 true SE8400788D0 (sv) 1984-02-14
SE8400788L SE8400788L (sv) 1984-08-19
SE456680B SE456680B (sv) 1988-10-24

Family

ID=23857582

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8400788A SE456680B (sv) 1983-02-18 1984-02-14 Derivat av 8-fenylxantin

Country Status (10)

Country Link
US (1) US4593095A (sv)
JP (1) JPS59205377A (sv)
BE (1) BE898946A (sv)
CA (1) CA1234804A (sv)
DE (1) DE3406275A1 (sv)
FR (1) FR2541281B1 (sv)
GB (2) GB8403574D0 (sv)
IT (1) IT1196031B (sv)
NL (1) NL8400514A (sv)
SE (1) SE456680B (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US5017577A (en) * 1986-04-25 1991-05-21 Burroughs Wellcome Co. Methods for treating viral infection
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
JPS63154687A (ja) * 1986-11-13 1988-06-27 マリオン・ラボラトリーズ・インコーポレーテッド 8ーアリールキサンチン
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
DE8817122U1 (sv) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (sv) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6930101B1 (en) * 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
ATE319452T1 (de) * 1999-10-29 2006-03-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen essstörungen
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
MXPA04004388A (es) 2001-11-09 2005-05-16 Cv Therapeutics Inc Antagonistas del receptor a2b de adenosina.
NZ528591A (en) * 2002-02-01 2006-11-30 King Pharmaceuticals Res & Dev 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
PT1789053E (pt) * 2004-09-01 2012-08-09 Gilead Sciences Inc Método de cicatrização de feridas utilizando antagonistas dos receptores de adenosina a2b
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド A2aアデノシンレセプターアゴニストの使用
WO2007092372A1 (en) * 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (ko) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ, インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2840559A (en) * 1954-06-22 1958-06-24 Krantz Jr Nuclearly substituted 8-theophyllines and method of making the same
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
BE636699A (sv) * 1962-08-31
EP0011399A1 (en) * 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines

Also Published As

Publication number Publication date
US4593095A (en) 1986-06-03
BE898946A (fr) 1984-06-18
GB8403574D0 (en) 1984-03-14
GB2135311B (en) 1986-11-05
CA1234804A (en) 1988-04-05
GB8404243D0 (en) 1984-03-21
GB2135311A (en) 1984-08-30
FR2541281B1 (fr) 1988-01-29
SE8400788L (sv) 1984-08-19
IT1196031B (it) 1988-11-10
FR2541281A1 (fr) 1984-08-24
IT8419675A0 (it) 1984-02-17
JPS59205377A (ja) 1984-11-20
SE456680B (sv) 1988-10-24
NL8400514A (nl) 1984-09-17
DE3406275A1 (de) 1984-09-27

Similar Documents

Publication Publication Date Title
SE8400788D0 (sv) Novel adenosine receptor antagonists
ATE30023T1 (de) Leukotrien-antagonisten.
NO851516L (no) Krysstang-kvadrupolkilde for akustisk broennlogging.
ES516374A0 (es) Procedimiento para la obtencion de composiciones poliolefinicas.
NO831341L (no) Laarbenkomponent for hofteleddprotese.
DK567884A (da) (bicyklisk heterocyclyl)holdige n-(bicyklisk heterocyclyl)-4-piperidinamider
FI842211A0 (fi) Kefalosporin derivat.
FI841505A (fi) Substituerade indeno-pyridazioner.
NO162353C (no) Lengderegulerbart boreroerstykke.
DE3482685D1 (de) Leukotrien-antagonisten.
FI840101A0 (fi) Ledanordning foer skjutvapen
ES540009A0 (es) Procedimiento de obtencion de polipeptidos
ES527234A0 (es) Procedimiento para la obtencion de 2-aril-4,6-dihalogenopirimidinas
FI841008A (fi) 7-oxabicykloheptansubstituerade prostaglandinanaloger.
IT8467449A1 (it) Procedimento per ottenere vetro piano ricoperto.
IT1179797B (it) Tornio per lavorazioni composite
ES523724A0 (es) Procedimiento de obtencion de fosfinamidas con efectos antitumorales.
ES536488A0 (es) Procedimiento de obtencion de 6-metil-19-nor-pregna 4, 6 dieno 3, 20-dionas
FR2555587B1 (fr) Derives de 14-des(hydroxymethyl)-mycaminosyltylonolide
AR240451A1 (es) Procedimiento para la obtenicon de pirrolidinonas.
FI830081A0 (fi) 6-aminoalkylpenicillansyra-1,1-dioxider och deras derivat som -laktamas-inhibitorer
DE69012388T2 (de) Selektive Adenosinrezeptor-Verbindungen.
DE69004455T2 (de) Alpha-adrenergene Rezeptor-Antagonisten.
IT8422749A0 (it) Derivati di as-triazine condensati.
MX9203754A (es) Antagonistas de leucotrieno.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8400788-9

Effective date: 19940910

Format of ref document f/p: F